A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.
Yu Pengfei(Zhejiang Cancer Hospital), Xiangdong Cheng(Hangzhou Cancer Hospital), Yian Du(Chinese Academy of Sciences), Zhiyuan Xu(Zhejiang Cancer Hospital), Ping Chen(Central South University), Yongxiang Wang(Shandong Provincial Hospital), Hongtao Xu(Lishui Central Hospital), Litao Yang(Shenzhen University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Nong Xu(First Affiliated Hospital Zhejiang University), Yunhai Wei(Huzhou Central Hospital)
Cited by 0
Related Papers
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417